Screener
Recursion Pharmaceuticals, Inc. RXRX Business Segments — Other income (loss), net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 41,533 | 46,653 | 76,124 | 101,304 |
| Total operating costs and expenses | 142,638 | 195,450 | 277,615 | 401,563 |
| Loss from operations | (134,968) | (176,227) | (263,472) | (367,595) |
| Other income (loss), net | 3,962 | 4,330 | 10,359 | (6,947) |
| Loss before income tax benefit | (131,006) | (171,897) | (253,113) | (374,542) |
| Income tax benefit | 1 | — | 4,604 | 158 |
| Net loss | $(131,005) | $(171,897) | $(248,509) | $(374,384) |
| Per share data |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — other income (loss), net of $3.96M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net decreased by 8.5% year-over-year, from $4.33M to $3.96M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net has grown at a -19.7% compound annual growth rate (CAGR), from $6.25M to $3.24M.
- What does business segments — other income (loss), net mean?
- Includes non-operating financial results, such as interest income, investment gains or losses, and other peripheral financial activities. This metric helps isolate the impact of non-core financial events from the segment's primary operational performance.
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude